Condition: Uveal Melanoma · Sponsor: Diwakar Davar
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
This description comes directly from the study's public registry record.
Amy Rose, RN, BSN · 412-647-8587 · kennaj@upmc.edu
Danielle L Bednarz, RN, BSN · 4126231191 · bertonsf@upmc.edu
Always discuss trial participation with your own doctor first.
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06070012